Skip to main content

Table 1 Baseline Characteristics

From: A phase 1, randomized, open-label, single-dose study to assess the relative bioavailability of a subcutaneous dose of FKB327 when administered using a prefilled syringe, a prefilled auto-injector, or a vial with disposable syringe in healthy subjects

 FKB327 vial
n = 66
FKB327 PFS
n = 63
FKB327 AI
n = 66
Total
n = 195
Age (years)
 Mean (SD)38 (13.6)40 (12.9)37 (12.5)38 (13.0)
Sex, n (%)
 Male50 (75.8)45 (71.4)50 (75.8)145 (74.4)
 Female16 (24.2)18 (28.6)16 (24.2)50 (25.6)
Race, n (%)
 Asian2 (3.0)4 (6.3)3 (4.5)9 (4.6)
 Black2 (3.0)1 (1.6)9 (13.6)12 (6.2)
 White62 (93.9)58 (92.1)53 (80.3)173 (88.7)
 Other1 (1.5)1 (0.5)
Weight (kg)
 Mean (SD)76.2 (10.37)75.2 (10.98)75.5 (11.56)75.6 (10.93)
BMI (kg/m2)
 Mean (SD)25.2 (3.06)25.2 (2.62)24.8 (2.85)25.1 (2.84)
  1. AI indicates prefilled autoinjector; BMI body mass index; PFS prefilled syringe; SD standard deviation; vial, vial with disposable syringe